SCHEMBL337203

SCHEMBL337203

CCOC(=O)c1cnc(Cl)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.61
TDP1 Q9NUW8 3/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
MAPK1 P28482 2/20 0.61
PKM P14618 1/20 0.54
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
P2RY12 Q9H244 5/20 0.50
MAPT P10636 1/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
APEX1 P27695 1/20 0.49
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31050105 1.00 ALDH1A1 (0.61) ALDH1A1TDP1L3MBTL1MAPK1PKM
SCHEMBL990850 0.87 CYP2C9 (0.53) ALDH1A1TDP1L3MBTL1MAPK1PKM
SCHEMBL15351663 0.85 CYP2C9 (0.51) ALDH1A1TDP1L3MBTL1MAPK1CYP2C9
SCHEMBL14332729 0.85 CA12 (0.54) ALDH1A1TDP1L3MBTL1MAPK1PKM
SCHEMBL5320922 0.84 CYP2C9 (0.50) ALDH1A1TDP1L3MBTL1MAPK1CYP2C9
SCHEMBL3950224 0.84 CYP2C9 (0.50) ALDH1A1TDP1L3MBTL1MAPK1PKM
SCHEMBL8276630 0.84 CYP2C9 (0.50) ALDH1A1TDP1L3MBTL1MAPK1PKM
SCHEMBL20482099 0.84 TDP1 (0.51) ALDH1A1TDP1L3MBTL1MAPK1PKM
SCHEMBL336406 0.84 CYP2C9 (0.50) ALDH1A1TDP1L3MBTL1MAPK1CYP2C9
SCHEMBL3922174 0.84 CYP2C9 (0.50) ALDH1A1TDP1L3MBTL1MAPK1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4644390-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-11-05 EP disclosed
WO-2024140850-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-07-04 WO disclosed
US-11976062-B2 Benzisoxazole compound OSAKA UNIVERSITY (JP) 2024-05-07 US disclosed
EP-3789383-B9 INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL UNIV OSAKA (JP) 2024-02-28 EP disclosed
EP-3789383-B1 INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL UNIV OSAKA (JP) 2023-11-29 EP disclosed
US-20230114195-A1 BENZISOXAZOLE COMPOUND KYOTO UNIVERSITY (JP) 2023-04-13 US disclosed
US-11548882-B2 Benzisoxazole compound OSAKA UNIVERSITY (JP) 2023-01-10 US disclosed
US-20210238171-A1 BENZISOXAZOLE COMPOUND INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (JP) 2021-08-05 US disclosed
WO-2021079962-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF HEARING LOSS 国立大学法人大阪大学 2021-04-29 WO disclosed
EP-3789383-A1 BENZISOXAZOLE COMPOUND Osaka University (JP) 2021-03-10 EP disclosed
US-20060122394-A1 Substituted biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2006-06-08 US disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 US disclosed
WO-2006026135-A2 SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES NEUROGEN CORPORATION (US) 2006-03-09 WO disclosed
EP-1632477-A1 BENZAMIDE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2006-03-08 EP disclosed
US-20060035939-A1 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2006-02-16 US disclosed
WO-2006016680-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) ASTELLAS PHARMA INC. (JP) 2006-02-16 WO disclosed
US-20050245538-A1 Proline derivatives and use thereof as drugs KITAJIMA HIROSHI 2005-11-03 US disclosed
WO-2005023759-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2005-03-17 WO disclosed
US-20040106655-A1 Proline derivatives and the use thereof as drugs MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-06-03 US disclosed
EP-1308439-A1 PROLINE DERIVATIVES AND USE THEREOF AS DRUGS WELFIDE CORPORATION (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238171-A1 BENZISOXAZOLE COMPOUND CBR1, CYP2S1, CYP2E1 ALDH1A1 201/4885TDP1 3298/4885L3MBTL1 2160/4885
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 ALDH1A1 1014/4885TDP1 2203/4885L3MBTL1 979/4885
US-11976062-B2 Benzisoxazole compound CBR1, CYP2S1, CYP2E1 ALDH1A1 202/4885TDP1 3335/4885L3MBTL1 2119/4885
US-11548882-B2 Benzisoxazole compound CBR1, CYP2S1, CYP2E1 ALDH1A1 201/4885TDP1 3298/4885L3MBTL1 2160/4885
US-20050245538-A1 Proline derivatives and use thereof as drugs DPP4, DPP3, DPP7 ALDH1A1 229/4885TDP1 1960/4885L3MBTL1 2628/4885
US-20060035939-A1 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity TRPV1, TRPV6, TRPV3 ALDH1A1 1481/4885TDP1 3664/4885L3MBTL1 2218/4885
US-20060122394-A1 Substituted biaryl piperazinyl-pyridine analogues GPR88, PRLHR, GPR68 ALDH1A1 801/4885TDP1 4129/4885L3MBTL1 3975/4885
US-20040106655-A1 Proline derivatives and the use thereof as drugs DPP4, DPP3, DPP7 ALDH1A1 118/4885TDP1 1115/4885L3MBTL1 2337/4885
US-20230114195-A1 BENZISOXAZOLE COMPOUND CBR1, CYP2S1, CYP2E1 ALDH1A1 184/4885TDP1 3069/4885L3MBTL1 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.